Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States

Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States

Michael Bogart,1 Lindsay GS Bengtson,2 Mary G Johnson,2 Scott H Bunner,2 Noelle N Gronroos,2 Kristi K DiRocco3 1US Value Evidence & Outcomes, R&D US, GSK, Research Triangle Park, NC, USA; 2Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA; 3USA, Medical Affairs, GSK, Colle...

Full description

Bibliographic Details
Main Authors: Bogart M, Bengtson LG, Johnson MG, Bunner SH, Gronroos NN, DiRocco KK
Format: Article
Language:English
Published: Dove Medical Press 2024-01-01
Series:International Journal of COPD
Subjects:
chronic obstructive pulmonary disease
triple therapy
multiple-inhaler triple therapy
single-inhaler triple therapy
adherence
exacerbations
Online Access:https://www.dovepress.com/outcomes-following-initiation-of-triple-therapy-with-fluticasone-furoa-peer-reviewed-fulltext-article-COPD

Internet

https://www.dovepress.com/outcomes-following-initiation-of-triple-therapy-with-fluticasone-furoa-peer-reviewed-fulltext-article-COPD

Similar Items